Lorbrena (lorlatinib)

pCPA File Number: 22304

Negotiation Status:

Concluded with an LOI

Indication(s):

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

PC0249-000

pCPA Engagement Letter Issued:

2023-03-20

Negotiation Process Concluded:

2023-05-19